Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 18/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.54 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | PIM1 | P11309 | 1/20 | 0.54 |
| ▸ | LTK | P29376 | 1/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.54 |
| ▸ | CDK8 | P49336 | 1/20 | 0.54 |
| ▸ | CDK9 | P50750 | 1/20 | 0.54 |
| ▸ | PRKX | P51817 | 1/20 | 0.54 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.54 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.54 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.54 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.54 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.54 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4857089 | 0.88 | CHEK1 (0.78) | CHEK1PIM1CDK8CDK9PRKX | |
| SCHEMBL4851811 | 0.82 | CHEK1 (0.69) | CHEK1AURKB | |
| SCHEMBL4852139 | 0.82 | CHEK1 (0.69) | CHEK1ABL1PIM1CDK8CDK9 | |
| SCHEMBL4858358 | 0.82 | CHEK1 (0.74) | CHEK1CLK4DAPK3PRKD3ABL1 | |
| SCHEMBL4856064 | 0.81 | CHEK1 (1.00) | CHEK1CLK4DAPK3PRKD3ABL1 | |
| SCHEMBL4860069 | 0.81 | CHEK1 (1.00) | CHEK1CLK4DAPK3PRKD3ABL1 | |
| SCHEMBL16712632 | 0.81 | CHEK1 (0.67) | CHEK1CLK4DAPK3PRKD3PIM1 | |
| SCHEMBL4857786 | 0.80 | CHEK1 (0.65) | CHEK1CLK4DAPK3PRKD3PIM1 | |
| SCHEMBL4851831 | 0.79 | CHEK1 (0.64) | CHEK1MAPK8AURKBCDK2IRAK4 | |
| SCHEMBL4850874 | 0.78 | CHEK1 (1.00) | CHEK1CLK4DAPK3PRKD3ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606268-B1 | 5,10-DIHYDRO-11H-DIBENZO[B,E][1,4]DIAZEPIN-11-ONE AS KINASE INHIBITORS | ABBVIE INC (US) | 2015-05-20 | — | — | EP | claimed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | claimed |
| US-20040254159-A1 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES | 2004-12-16 | — | — | US | claimed |
| EP-1606268-B1 | 5,10-DIHYDRO-11H-DIBENZO[B,E][1,4]DIAZEPIN-11-ONE AS KINASE INHIBITORS | ABBVIE INC (US) | 2015-05-20 | — | — | EP | disclosed |
| US-7456169-B2 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
| US-20040254159-A1 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254159-A1 | Heterocyclic kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | CHEK1 46/4885CLK4 701/4885DAPK3 284/4885 |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | CHEK1 38/4885CLK4 652/4885DAPK3 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.